Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in chronic spontaneous urticaria inadequately controlled by antihistamines and prior anti-IgE
jRCT2031210170Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of tezepelumab in chronic idiopathic urticaria (CIU) (4 arms), sponsored by Amgen. Primary endpoint: Change from Baseline in Urticaria Activity Score over 7 days (UAS7) at Week 16. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2031210170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210170.